EcoDrugPlus

Bcl2 Like 2

Ensembl ID : ENSLLEG00000014994
Gene Symbol: BCL2L2
1 View Cross-references
64 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSLLEG00000001311
Gene Symbol: BCR
1 View Cross-references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bruton Tyrosine Kinase

Ensembl ID : ENSLLEG00000017201
Gene Symbol: BTK
1 View Cross-references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSLLEG00000005950
Gene Symbol: CXCR4
1 View Cross-references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSLLEG00000008811
Gene Symbol: CFTR
1 View Cross-references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Methyltransferase 1

Ensembl ID : ENSLLEG00000004264
Gene Symbol: DNMT1
1 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase I

Ensembl ID : ENSLLEG00000027347
Gene Symbol: TOP1
1 View Cross-references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSLLEG00000021404
Gene Symbol: TOP2A
1 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dna Topoisomerase Ii Beta

Ensembl ID : ENSLLEG00000017710
Gene Symbol: TOP2B
1 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Emap Like 4

Ensembl ID : ENSLLEG00000015786
Gene Symbol: EML4
1 View Cross-references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor A2

Ensembl ID : ENSLLEG00000024860
Gene Symbol: EPHA2
1 View Cross-references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Eph Receptor A3

Ensembl ID : ENSLLEG00000000599
Gene Symbol: EPHA3
1 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).